All In Biotech

Drug Trial Radar · NCT01146951

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients

Last checked: Nov 19, 2026Latest source record: Jan 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

66

Actual

Start

Jun 2010

Primary completion

Aug 2011

Study completion Aug 2011

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
First posted
Jun 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.

Conditions

  • Lennox-Gastaut Syndrome

Interventions

  • Rufinamide (E2080)Drug

    Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period. Target maintenance dose: 15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)

  • PlaceboDrug

    Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)Time frame: Baseline (28 day observational period) and End of Treatment (28 day treatment period)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Matsuyama, Ehime, Japan

  • Site not named

    Fukuoka, Fukuoka, Japan

  • Site not named

    Hiroshima, Hiroshima, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Yokohama, Kanagawa, Japan

  • Site not named

    Goshi-shi, Kumamoto, Japan

  • Site not named

    Iwamuma-shi, Miyagi, Japan

  • Site not named

    Omura-shi, Nagasaki, Japan

  • Site not named

    Nara, Nara, Japan

  • Site not named

    Niigata, Niigata, Japan

  • Site not named

    Yufu-shi, Oita Prefecture, Japan

  • Site not named

    Okayama, Okayama-ken, Japan

  • Site not named

    Neyagawa, Osaka, Japan

  • Site not named

    Osaka, Osaka, Japan

  • Site not named

    Suita-shi, Osaka, Japan

  • Site not named

    Moriya-shi, Shiga, Japan

  • Site not named

    Shizuoka, Shizuoka, Japan

  • Site not named

    Kodaira-shi, Tokyo, Japan

  • Site not named

    Kokubunji-shi, Tokyo, Japan

  • Site not named

    Shinjuku-ku, Tokyo, Japan

  • Site not named

    Toyoma-shi, Toyama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.